pegylated liposomal doxorubicin (PLD) + PD-1
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Muscle Invasive Bladder Cancer
Conditions
Muscle Invasive Bladder Cancer
Trial Timeline
Sep 17, 2019 → May 31, 2021
NCT ID
NCT04101812About pegylated liposomal doxorubicin (PLD) + PD-1
pegylated liposomal doxorubicin (PLD) + PD-1 is a phase 2 stage product being developed by CSPC Pharmaceutical Group Limited for Muscle Invasive Bladder Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT04101812. Target conditions include Muscle Invasive Bladder Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04101812 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Muscle Invasive Bladder Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enfortumab vedotin + Pembrolizumab | Astellas Pharma | Phase 2 | 52 |
| Enfortumab Vedotin + Pembrolizumab | Astellas Pharma | Phase 2 | 52 |
| Pembrolizumab + Enfortumab Vedotin | Astellas Pharma | Phase 3 | 77 |
| Eperisone | Eisai | Phase 3 | 77 |
| LY2495655 + Placebo | Eli Lilly | Phase 2 | 52 |
| HRS-9190 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| HRS-9190 for Injection | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Botulinum Toxin Type A | AbbVie | Phase 3 | 77 |
| BOTOX + Placebo | AbbVie | Phase 3 | 77 |
| BOTOX + Placebo | AbbVie | Phase 3 | 77 |
| BOTOX + Placebo for BOTOX | AbbVie | Phase 3 | 77 |
| BOTOX + Placebo | AbbVie | Phase 3 | 77 |
| Durvalumab + Tremelimumab + Enfortumab Vedotin | AstraZeneca | Phase 3 | 77 |
| Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG) | AstraZeneca | Phase 3 | 77 |
| Durvalumab + Oleclumab | AstraZeneca | Phase 1 | 33 |
| AZD4547 + MEDI4736 + Olaparib + AZD1775 + Vistusertib + AZD9150 + Selumetinib | AstraZeneca | Phase 1 | 33 |
| Durvalumab + Cisplatin + Gemcitabine | AstraZeneca | Phase 3 | 77 |
| Durvalumab + BCG | AstraZeneca | Phase 3 | 77 |
| Durvalumab + Monalizumab | AstraZeneca | Phase 2 | 52 |
| Durvalumab (Imfinzi) + Tremelimumab | AstraZeneca | Phase 2 | 52 |
Other Products from CSPC Pharmaceutical Group Limited
Butylphthalide + Butylphthalide placeboPhase 3
76
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenPhase 2
51
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsPhase 2
51
Sintilimab + Nab paclitaxel + CisplatinPhase 2
51
liposomal irinotecan monotherapy + liposomal irinotecan monotherapy + Liposomal Irinotecan + rmhTNF-NC + Liposomal Irinotecan + BevacizumabPhase 1/2
40